

## MESOBLAST RECEIVES \$4.3 MILLION FROM AUSTRALIAN GOVERNMENT FOR ADULT STEM CELL PIPELINE DEVELOPMENT

**Melbourne, Australia; 18 July 2013:** Mesoblast Limited today announced that it has received approximately \$4.3 million under the Australian Government's Innovation Australia Research and Development (R&D) Tax Incentive Program for R&D activities conducted in Australia during the 2012 financial year.

The funds will be used to advance development of Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) technology platform and product pipeline.

Based on the Company's ongoing clinical and research activities in Australia across its product portfolio, Mesoblast anticipates that it will make additional submissions in FY2013 and be eligible to receive further reimbursements.

### About Mesoblast

Mesoblast Limited (ASX:MSB; USOTC:MBLTY) is a world leader in the development of biologic products for the broad field of regenerative medicine. The Company's technologies include its proprietary adult Mesenchymal Precursor Cell (MPC) technology platform for bone marrow and adipose tissue derived products, Dental Pulp Stem Cells (DPSCs) and expanded Hematopoietic Stem Cells (HSCs). Mesoblast's allogeneic or 'off-the-shelf' regenerative medicine products focus on repair of damaged tissues and modulation of inflammatory responses in conditions with significant unmet medical needs. The lead product candidates use its MPC platform in three major and distinct areas - systemic inflammatory conditions, cardiovascular diseases and orthopedic diseases of the spine. [www.mesoblast.com](http://www.mesoblast.com)

*For further information, please contact:*

Julie Meldrum  
Corporate Communications  
Mesoblast Limited  
T: +61 (0) 3 9639 6036

E: [julie.meldrum@mesoblast.com](mailto:julie.meldrum@mesoblast.com)

**Mesoblast Limited**  
ABN 68 109 431 870  
[www.mesoblast.com](http://www.mesoblast.com)

**Corporate Headquarters**  
Level 39  
55 Collins Street  
Melbourne 3000  
Victoria Australia  
T +61 3 9639 6036  
F +61 3 9639 6030

**United States Operations**  
505 Fifth Avenue  
Third Floor  
New York, NY 10017  
USA  
T +1 212 880 2060  
F +1 212 880 2061

**Asia**  
20 Biopolis Way  
#05-01 Centros  
Biopreneur 3  
SINGAPORE 138668  
T +65 6570 0635  
F +65 6570 0176